ArticleCornea2019
Short- and Long-Term Results of Xenogeneic-Free Cultivated Autologous and Allogeneic Limbal Epithelial Stem Cell Transplantations.
Article in Cornea, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- In situ spatial transcriptomics reveals novel markers of the limbal stem cell niche and ocular surface epithelia.Stem cell reports · 2026Article
- Progenitor cells from limbal, conjunctival and oral mucosal biopsies cultivated on silicone hydrogel contact lenses share CD90, CK15, nestin, CXCR4 and SDF-1 niche markers but preserve tissue-specific characteristics and differentiation directions.Frontiers in cell and developmental biology · 2026Article
- Reprogramming of Human Limbal Niche Progenitors.International journal of medical sciences · 2026Review
- Ocular Surface Regeneration by Limbal Stem Cells Therapies: State of the Art, Challenges, and Perspectives.Stem cells translational medicine · 2023Article
- Bone metastasis in a case of primary acquired melanosis with atypia resulting from conjunctiva melanoma.American journal of ophthalmology case reports · 2023Article
- Concise Review: Bioengineering of Limbal Stem Cell Niche.Bioengineering (Basel, Switzerland) · 2023Review
- Profile of biological characterizations and clinical application of corneal stem/progenitor cells.World journal of stem cells · 2022Review
- Current and Emerging Therapies for Limbal Stem Cell Deficiency.Stem cells translational medicine · 2022Article
- Human limbal epithelial stem cell regulation, bioengineering and function.Progress in retinal and eye research · 2021Review
- A Decellularized Human Limbal Scaffold for Limbal Stem Cell Niche Reconstruction.International journal of molecular sciences · 2021Article
- Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency.Pharmaceutics · 2021Review
- Stem Cells in the Path of Light, from Corneal to Retinal Reconstruction.Biomedicines · 2021Review
- Process development and safety evaluation of ABCB5Stem cell research & therapy · 2021Article
- Corneal Repair with Adhesive Cell Sheets of Fetal Cartilage-Derived Stem Cells.Tissue engineering and regenerative medicine · 2021Article
- Recent Advances in Stem Cell Therapy for Limbal Stem Cell Deficiency: A Narrative Review.Ophthalmology and therapy · 2020Review
- Expansion of Human Limbal Epithelial Stem/Progenitor Cells Using Different Human Sera: A Multivariate Statistical Analysis.International journal of molecular sciences · 2020Article
- Clinical Outcomes From Cultivated Allogenic Stem Cells vs. Oral Mucosa Epithelial Transplants in Total Bilateral Stem Cells Deficiency.Frontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the short- and long-term success rates of xenogeneic-free cultivated limbal epithelial stem cell transplantation (CLET) for the treatment of limbal stem cell deficiency (LSCD).
methodsThirteen patients with LSCD underwent an autologous (n = 9) or allogeneic (n = 4) CLET. The primary end point was to assess the long-term anatomical success rate of transplanted grafts at a follow-up of at least 3 years, in comparison with the short-term outcomes. Secondary end points involved reviewing functional improvement, patient-reported symptoms, and change in percentage area of corneal vascularization in both short-term and long-term.
resultsThe mean short- and long-term follow-up periods were 2.1 ± 0.38 years and 6.7 ± 1.81 years, respectively. The total anatomical success rate was 46.1% in the short-term, but it decreased to 23.1% in the long-term. A partial success rate of 30.8% was observed in both short- and long-term, and the failure rate increased from 23.1% to 46.1%. The mean percentage of vessel area decreased from 12.11% ± 5.29% preoperatively to 7.82% ± 6.70% in the short-term and increased to 8.70% ± 6.32% in the long-term. There was a significant improvement in best-corrected visual acuity (P = 0.044) in the short-term although not in the long-term (P = 0.865).
conclusionsThis study shows that anatomical and functional success rates of CLET decrease over time. We believe that the decline of success is related to the extent of disease, cell origin, and lack of niche protection because subtotal LSCD and autologous donor cells confer a higher chance of success in the long-term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.